Healthy children generally have a mild illness with SARS-COV-2; however, some comorbidities may predispose to severe COVID-19 disease. Neurological conditions were the predominant comorbidity of hospitalised children in the UK with COVID-19 (11%)1 and a larger proportion (26%) of those with severe/fatal disease.2 Children perceived to be at highest risk of COVID-19 were shielded, reducing risks of infection and therefore underrepresented in the data. Vaccination safety data for BNT162b2 (Pfizer-Bio-N-Tech) is now available from healthy adolescents age 12 to 15 years. Similar to adult studies, common side effects were mild-moderate pain at injection site (86%), fatigue (66%), headache (65%), and fever ≥38°C (20%).3 Although the side effects from adult studies were mild, they were inversely related to age, that is, younger participants (<55 years) had more side effects.4 The Joint Committee on Vaccination and Immunisation (JCVI) advised …

中文翻译：

---

BNT162b2 (Pfizer-Bio-N-Tech) 疫苗在 12-15 岁极度脆弱儿童中的安全性和耐受性初步体验

健康的儿童通常患有 SARS-COV-2 的轻度疾病；然而，一些合并症可能会导致严重的 COVID-19 疾病。神经系统疾病是英国 COVID-19 住院儿童的主要合并症（11%）1 和更大比例（26%）患有严重/致命疾病的儿童。2 被认为感染 COVID-19 风险最高的儿童是屏蔽，降低感染风险，因此在数据中的代表性不足。BNT162b2 (Pfizer-Bio-N-Tech) 的疫苗接种安全数据现在可从 12 至 15 岁的健康青少年获得。与成人研究相似，常见的副作用是注射部位轻度中度疼痛 (86%)、疲劳 (66%)、头痛 (65%) 和 ≥38°C (20%)。成人研究是温和的，它们与年龄成反比，也就是说，年轻的参与者（<